KMDA
Kamada
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 2
consensus rating "Strong Buy"
Upward Gap
EPS Below Expectations
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About KMDA
Kamada Ltd.
A vertically integrated global biopharmaceutical company that focused on specialty plasma-derived therapeutics
2 Holzman St., Weizmann Science Park, P.O Box 4081, Rehovot 7670402, Israel
Plasma-derived protein therapy companies that market existing rare combination drug products.
Kamada Ltd., was established in Israel on December 13, 1990. The company is a commercial-stage global biopharmaceutical company with a marketed product portfolio for rare and serious diseases, and is a leader in the field of specialized plasma derivation focusing on limited therapeutic alternative diseases. The company is also advancing an innovative development pipeline for areas with significant unmet medical needs. The company's strategy is focused on driving profitable growth from the company's important commercial catalysts and the company's manufacturing and development expertise in the plasma-derived and biopharmaceutical markets.
Company Financials
EPS
KMDA has released its 2024 Q4 earnings. EPS was reported at 0.07, versus the expected 0.05, beating expectations. The chart below visualizes how KMDA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
KMDA has released its 2024 Q4 earnings report, with revenue of 39.01M, reflecting a YoY change of 7.06%, and net profit of 3.81M, showing a YoY change of -24.71%. The Sankey diagram below clearly presents KMDA’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
